2018
Frequency and Outcomes of Reduced Dose Non–Vitamin K Antagonist Anticoagulants: Results From ORBIT‐AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II)
Steinberg BA, Shrader P, Pieper K, Thomas L, Allen LA, Ansell J, Chan PS, Ezekowitz MD, Fonarow GC, Freeman JV, Gersh BJ, Kowey PR, Mahaffey KW, Naccarelli GV, Reiffel JA, Singer DE, Peterson ED, Piccini JP, Investigators T. Frequency and Outcomes of Reduced Dose Non–Vitamin K Antagonist Anticoagulants: Results From ORBIT‐AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II). Journal Of The American Heart Association 2018, 7: e007633. PMID: 29453305, PMCID: PMC5850192, DOI: 10.1161/jaha.117.007633.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAgedAged, 80 and overAnticoagulantsAtrial FibrillationDrug Dosage CalculationsDrug PrescriptionsFemaleGuideline AdherenceHemorrhageHumansMaleMiddle AgedPractice Guidelines as TopicPractice Patterns, Physicians'Prospective StudiesRegistriesStrokeTime FactorsTreatment OutcomeUnited StatesConceptsDrug Administration labelingAtrial fibrillationNOAC doseAF patientsDose reductionNon-vitamin K antagonist anticoagulantsUS FoodORBIT-AF II registryInappropriate dose reductionOutcomes of patientsHigher unadjusted ratesCommunity practiceDrug Administration recommendationsNOAC dosesStandard dosingObservational registryOral anticoagulantsStroke preventionThromboembolic eventsUnadjusted ratesCertain patientsStandard doseNOACsPatterns of useRisk score
2017
Treatment of Atrial Fibrillation and Concordance With the American Heart Association/American College of Cardiology/Heart Rhythm Society Guidelines
Barnett AS, Kim S, Fonarow GC, Thomas LE, Reiffel JA, Allen LA, Freeman JV, Naccarelli G, Mahaffey KW, Go AS, Kowey PR, Ansell JE, Gersh BJ, Hylek EM, Peterson ED, Piccini JP. Treatment of Atrial Fibrillation and Concordance With the American Heart Association/American College of Cardiology/Heart Rhythm Society Guidelines. Circulation Arrhythmia And Electrophysiology 2017, 10: e005051. PMID: 29141842, DOI: 10.1161/circep.117.005051.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAmerican Heart AssociationAtrial FibrillationCardiologistsFemaleGuideline AdherenceHealthcare DisparitiesHumansMaleMiddle AgedPractice Guidelines as TopicPractice Patterns, Physicians'Process Assessment, Health CareQuality Indicators, Health CareRegistriesRetrospective StudiesTime FactorsTreatment OutcomeUnited StatesConceptsAmerican Heart Association/American CollegeAtrial fibrillationGuideline recommendationsAmerican CollegeCardiology/Heart Rhythm Society GuidelinesHeart Rhythm Society guidelinesAtrial fibrillation guidelinesGuideline-concordant careThird of patientsRisk-adjusted outcomesAntiarrhythmic medicationsGuideline concordanceMajor bleedingMedian CHAOutpatient registryVASc scoreAntithrombotic therapyCause hospitalizationMedian ageClinical outcomesSociety guidelinesORBIT-AFImproved outcomesPatient levelSimilar risk
2013
Effectiveness and Safety of Digoxin Among Contemporary Adults With Incident Systolic Heart Failure
Freeman JV, Yang J, Sung SH, Hlatky MA, Go AS. Effectiveness and Safety of Digoxin Among Contemporary Adults With Incident Systolic Heart Failure. Circulation Cardiovascular Quality And Outcomes 2013, 6: 525-533. PMID: 24021697, DOI: 10.1161/circoutcomes.111.000079.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAgedAged, 80 and overCaliforniaCardiotonic AgentsChi-Square DistributionDigoxinDisease ProgressionDrug Therapy, CombinationFemaleGuideline AdherenceHealth Maintenance OrganizationsHeart Failure, SystolicHospitalizationHumansIncidenceMaleMiddle AgedMultivariate AnalysisPractice Guidelines as TopicProportional Hazards ModelsRisk FactorsSex FactorsTime FactorsTreatment OutcomeConceptsIncident systolic heart failureSystolic heart failureSafety of digoxinΒ-blocker useDigoxin useHeart failureHF hospitalizationConcurrent β-blocker useSymptomatic systolic heart failureKaiser Permanente Northern CaliforniaHF disease severityOptimal medical therapyRisk of deathMedical therapyMultivariable analysisContemporary cohortCox regressionClinical guidelinesMedical historyHigh riskHospitalizationHigh mortalityPatientsDisease severityTrial dataUse of Evidence-based Cardiac Prevention Therapy Among Outpatients with Atrial Fibrillation
Hess PL, Kim S, Piccini JP, Allen LA, Ansell JE, Chang P, Freeman JV, Gersh BJ, Kowey PR, Mahaffey KW, Thomas L, Peterson ED, Fonarow GC. Use of Evidence-based Cardiac Prevention Therapy Among Outpatients with Atrial Fibrillation. The American Journal Of Medicine 2013, 126: 625-632.e1. PMID: 23787195, PMCID: PMC4037289, DOI: 10.1016/j.amjmed.2013.01.037.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntihypertensive AgentsAtrial FibrillationCardiovascular DiseasesComorbidityDefibrillators, ImplantableEvidence-Based PracticeFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsLogistic ModelsMalePlatelet Aggregation InhibitorsPractice Guidelines as TopicRegistriesRisk FactorsConceptsCardiovascular comorbid conditionsEvidence-based therapiesAtrial fibrillationRisk factorsComorbid conditionsEvidence-based therapy useMore evidence-based therapiesGuideline-recommended therapiesAngiotensin receptor blockersAntiarrhythmic drug therapyCardiovascular risk factorsPeripheral vascular diseaseMinority of patientsCoronary artery diseaseMultivariable logistic regressionUS national registryAngiotensin-converting enzymeAldosterone antagonistsComorbid illnessesReceptor blockersComorbid diseasesAntiplatelet agentsArtery diseaseDiabetes mellitusHeart failure
2012
Effectiveness of Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy in Heart Failure
Freeman JV, Masoudi FA. Effectiveness of Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy in Heart Failure. Heart Failure Clinics 2012, 9: 59-77. PMID: 23168318, DOI: 10.1016/j.hfc.2012.09.006.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedCardiac Resynchronization TherapyComparative Effectiveness ResearchDefibrillators, ImplantableDisease ManagementFemaleHeart FailureHumansMaleMeta-Analysis as TopicMiddle AgedObservationOutcome and Process Assessment, Health CarePatient SelectionPractice Guidelines as TopicRandomized Controlled Trials as TopicSecondary PreventionSeverity of Illness IndexSex FactorsSurvival RateConceptsCardiac resynchronization therapyTrial dataResynchronization therapyQRS morphologyNYHA class IV patientsCardiac devicesBenefit of ICDSingle-chamber ICDClass IV patientsHigh-volume hospitalsOptimal medical managementEffective treatment modalityPrior ventricular arrhythmiasProlonged QRS complexRecent trial dataRecent trial resultsImplantable cardioverter defibrillatorQuality of lifeHF hospitalizationSymptomatic HFHF symptomsICD therapySevere comorbiditiesIV patientsMortality benefit
2011
Interpretation of the Electrocardiogram of Young Athletes
Uberoi A, Stein R, Perez MV, Freeman J, Wheeler M, Dewey F, Peidro R, Hadley D, Drezner J, Sharma S, Pelliccia A, Corrado D, Niebauer J, Estes NA, Ashley E, Froelicher V. Interpretation of the Electrocardiogram of Young Athletes. Circulation 2011, 124: 746-757. PMID: 21824936, DOI: 10.1161/circulationaha.110.013078.Peer-Reviewed Original ResearchAdolescentAdultAthletesBrugada SyndromeCardiologyChildConfounding Factors, EpidemiologicDeath, Sudden, CardiacDiagnosis, DifferentialElectrocardiographyEuropeExerciseFemaleHeart VentriclesHumansHypertrophy, Left VentricularHypertrophy, Right VentricularLong QT SyndromeMaleMass ScreeningMiddle AgedOrgan SizePractice Guidelines as TopicReference ValuesSocieties, MedicalYoung Adult